Pfizer to launch new antibiotic Zavicefta in UK and Germany

Pfizer Inc. today announced that Zavicefta, a combination of antibiotics for the treatment of some Gram-negative bacterial infections requiring hospitalization, is now available in the UK and Germany. The company plans to launch the drug in additional markets outside the US throughout 2017 and 2018. The product was authorized in Europe last June, being indicated for the treatment of adults with cIAI (complicated intra-abdominal infection), cUTI (complicated urinary tract infection) and HAP (Hospital-Acquired Pneumonia), including VAP (Ventilator Associated Pneumonia). The product is also intended for the treatment of infections due to Gram-negative organisms in adult patients with limited treatment options. Specifically, Zavicefta addresses Pseudomonas Aeruginosa and Enterobacteriaceae, two of the three pathogens recently identified by the World Health Organization as serious and critical due to their antimicrobial resistance.
(Source: Business Wire)